Even without international partnerships or offices, this recommended Düsseldorf firm would be excellently set for the UPC thanks to its outstanding litigation expertise. The patent attorneys are viewed as experienced in litigating for pharmaceuticals and mechanics patents. At national level too, the firm is a popular candidate for difficult proceedings of a precedent nature, e.g. work for Eli Lilly concerning Alimta in the matter of equivalent patent infringement. The firm’s litigation experience no longer centers on just König. Von Renesse, Max Tilmann and, most recently, Roth are also visible in the market. As long as the UPC launch remains uncertain, König Szynka can rely on its national litigation expertise and solid filing activity.
Litigation by patent attorneys, often in cases of a precedent nature, primarily for biotech and pharmaceuticals companies; mechanics patents.
Gregor König, Dr. Dirk Szynka, Max Tilmann, Dr. Dorothea von Renesse, Carla Roth (all patent attorneys).
13 patent attorneys
Exclusive activity in IP with a clear focus on patents. Patent filing with a broad technical spectrum. Extensive litigation work in cooperation with external lawyers. Also patent assessments and licensing contracts.
Public knowledge: Bayer Pharma regarding drospirenone; Eli Lilly concerning Alimta; Abbvie in opposition suits; OrbusNeich regarding stents; Ethical Coffee Company regarding coffee capsules; frequent litigation: Geberit and Shimano; filing for Orthogen, Osram, Paion, Qiagen, Takeda.